Form 4: Director Anthony C. Hooper Receives BeOne Medicines Equity

Director Anthony C. Hooper acquired 18,980 restricted share units in BeOne Medicines Ltd. as part of director compensation.

Summary

• Director Anthony C. Hooper was granted 18,980 restricted share units (RSUs) in BeOne Medicines Ltd. (ONC).
• The transaction occurred on June 11, 2026, at a price of $0 per share, representing an equity-based compensation grant.
• Following this transaction, Mr. Hooper's total beneficial ownership of ordinary shares increased to 83,720 shares.
• The RSUs are subject to a vesting schedule tied to the first anniversary of the grant or the next annual general meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Increase in total beneficial ownership by a member of the board.

Negatives

• None identified in this filing.

Risks

• Vesting is contingent upon continued service on the board of directors.
• Potential for accelerated vesting is subject to specific conditions defined in the company's Independent Non-Executive Director Compensation Policy.

Future Outlook

The RSUs will vest on the earlier of the first anniversary of the grant date or the date of the next annual general meeting, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to non-executive directors are standard corporate governance practice in the biotechnology sector to ensure long-term alignment between board members and shareholders.

Comparison to Industry Standards

• The use of RSUs for director compensation is consistent with standard practices for publicly traded biotech firms.
• The vesting period of one year or the next annual meeting is a common benchmark for director equity awards.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact; reflects standard director compensation practices.

Next Steps

• Vesting of the 18,980 restricted share units on the earlier of June 11, 2027, or the next annual general meeting.

Key Dates

Keywords

BeOne Medicines, ONC, Form 4, Insider Trading, Director Compensation, Restricted Share Units